BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33971648)

  • 1. Neonatal Withdrawal Syndrome following Late in utero Exposure to Selective Serotonin Reuptake Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies.
    Wang J; Cosci F
    Psychother Psychosom; 2021; 90(5):299-307. PubMed ID: 33971648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.
    Eke AC; Saccone G; Berghella V
    BJOG; 2016 Nov; 123(12):1900-1907. PubMed ID: 27239775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database.
    Gastaldon C; Arzenton E; Raschi E; Spigset O; Papola D; Ostuzzi G; Moretti U; Trifirò G; Barbui C; Schoretsanitis G
    Psychol Med; 2023 Sep; 53(12):5645-5653. PubMed ID: 36128628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome.
    Koren G; Moretti M; Kapur B
    J Obstet Gynaecol Can; 2006 Apr; 28(4):299-301. PubMed ID: 16776907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
    Nordeng H; Lindemann R; Perminov KV; Reikvam A
    Acta Paediatr; 2001 Mar; 90(3):288-91. PubMed ID: 11332169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
    Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
    Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.
    Levinson-Castiel R; Merlob P; Linder N; Sirota L; Klinger G
    Arch Pediatr Adolesc Med; 2006 Feb; 160(2):173-6. PubMed ID: 16461873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy].
    Cissoko H; Swortfiguer D; Giraudeau B; Jonville-Béra AP; Autret-Leca E
    Arch Pediatr; 2005 Jul; 12(7):1081-4. PubMed ID: 15964522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
    Shea AK; Wang DY; Snelgrove JW; Dalfen A; Hewko S; Murphy KE
    J Obstet Gynaecol Can; 2021 Jun; 43(6):726-732. PubMed ID: 33303407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.
    Moses-Kolko EL; Bogen D; Perel J; Bregar A; Uhl K; Levin B; Wisner KL
    JAMA; 2005 May; 293(19):2372-83. PubMed ID: 15900008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of breastfeeding newborns in the first month of life with in utero selective serotonin reuptake inhibitor medication exposure: a scoping review protocol.
    Cantin C; Snelgrove-Clarke E; Gaudet L; Ross-White A
    JBI Evid Synth; 2024 Jan; 22(1):144-152. PubMed ID: 37799099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis.
    Ng QX; Venkatanarayanan N; Ho CYX; Sim WS; Lim DY; Yeo WS
    J Womens Health (Larchmt); 2019 Mar; 28(3):331-338. PubMed ID: 30407100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
    de Moor RA; Mourad L; ter Haar J; Egberts AC
    Ned Tijdschr Geneeskd; 2003 Jul; 147(28):1370-2. PubMed ID: 12892015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome.
    Klinger G; Merlob P
    Isr J Psychiatry Relat Sci; 2008; 45(2):107-13. PubMed ID: 18982836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in Resting-State Networks Following In Utero Selective Serotonin Reuptake Inhibitor Exposure in the Neonatal Brain.
    Rotem-Kohavi N; Williams LJ; Virji-Babul N; Bjornson BH; Brain U; Werker JF; Grunau RE; Miller SP; Oberlander TF
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 Jan; 4(1):39-49. PubMed ID: 30292808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
    Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
    J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.
    Sanz EJ; De-las-Cuevas C; Kiuru A; Bate A; Edwards R
    Lancet; 2005 Feb 5-11; 365(9458):482-7. PubMed ID: 15705457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.
    Tuccori M; Testi A; Antonioli L; Fornai M; Montagnani S; Ghisu N; Colucci R; Corona T; Blandizzi C; Del Tacca M
    Clin Ther; 2009 Jun; 31 Pt 1():1426-53. PubMed ID: 19698902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of In-utero Exposure to Selective Serotonin Reuptake Inhibitors and Opioids on Neonatal Opioid Withdrawal Syndrome.
    Bhatt-Mehta V; Richards J; Sturza J; Schumacher RE
    J Addict Med; 2019; 13(3):227-234. PubMed ID: 30489344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.